Amgen Inc. (AMGN)

Amgen's stock price has experienced fluctuations over the past six months, with a 6.9% return in this period, but a -11.03% return over the past three months and a -0.46% return over the past 30 days. These fluctuations were influenced by positive clinical trial results, financial results, dividend declarations, an Otezla impairment charge, regulatory approvals, and manufacturing expansion.

Amgen's stock exhibits a strong seasonal pattern from June 30 to September 1, with average returns of +8.58% and a 76% win rate, suggesting that investors may view healthcare stocks like Amgen as defensive investments during the summer months. Enbrel sales have shown seasonal impacts on price and inventory levels, with sales growing quarter-over-quarter following such seasonal effects.

Amgen Inc. is a leading global biopharmaceutical company specializing in the discovery, development, manufacturing, and delivery of innovative human therapeutics. The company operates within the biotechnology sector and the drug manufacturing industry, focusing on areas of high unmet medical need. Amgen's core business revolves around biologic medicines that address a range of serious illnesses across several therapeutic areas, including oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen's major products include Enbrel, Prolia, XGEVA, Repatha, Otezla, Neulasta, Neupogen, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, and KRYSTEXXA. Amgen also has a growing biosimilar portfolio, including Mvasi, Kanjinti, and Amgevita.

Amgen maintains a robust global footprint with a presence in approximately 100 countries and regions worldwide, including research and development facilities, manufacturing sites, and commercial operations across North America, Europe, Asia Pacific, and emerging markets. The company's revenue reporting is primarily divided into two regions: the United States and the Rest of World (ROW).

Amgen has received positive recognition for its brand reputation in the past year, including being named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes. No specific negative events significantly impacted Amgen's brand reputation in the past year were found in the search results.

Amgen Inc. is primarily owned by institutional shareholders, who hold 78.24% of the company's stock, while Amgen insiders own 1.00%, and retail investors hold 20.77%. Major institutional owners include Vanguard Group Inc., BlackRock Inc., State Street Corp, Capital World Investors, Morgan Stanley, Capital International Investors, Geode Capital Management LLC, Primecap Management Co, Charles Schwab Investment Management Inc., and Wells Fargo Company.